FindTrial
Sign In

Rifapentine (RPT)

DRUG6 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Walter K. Kraft, Shandong University

Conditions

Drug Interaction PotentiationHIV InfectionHIV InfectionsHuman Immunodeficiency VirusLTBILatent TuberculosisMild Spinal TuberculosisRifamycins Causing Adverse Effects in Therapeutic Use

Phase 1

Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults
CompletedNCT01574638
National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis
Start: 2012-06-30End: 2013-06-30Updated: 2021-11-05
Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women
CompletedNCT02651259
National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis
Start: 2017-03-13End: 2019-04-10Updated: 2021-11-04
Doravirine, Rifapentine and Isoniazid Interaction
CompletedNCT03886701
Walter K. KraftDrug Interaction Potentiation, Human Immunodeficiency Virus, Latent Tuberculosis +1
Start: 2019-04-22End: 2019-05-20Updated: 2020-03-27

Phase 2

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
TerminatedNCT04272242
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection, LTBI
Start: 2021-02-27End: 2021-12-27Updated: 2024-09-19
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
Not yet recruitingNCT06917495
Shandong UniversityMild Spinal Tuberculosis
Start: 2025-04-05End: 2029-12-31Target: 300Updated: 2025-04-08

Phase 3

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
CompletedNCT01404312
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Tuberculosis
Start: 2012-05-23End: 2017-11-14Updated: 2021-11-04

Related Papers

Rifapentine- and moxifloxacin-containing short-course regimens for mild spinal tuberculosis: study protocol for a multicenter, randomized, non-inferiority phase II clinical trial.
2025-12-191 citations
Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention
Clinical Infectious Diseases2024-04-035 citations
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
2022-08-094 citations
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
Clinical Infectious Diseases2021-07-2830 citations
Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy Volunteers
UNC Libraries2020-10-31
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine
Pharmacogenetics and Genomics2020-08-1712 citations
Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials
Clinical Infectious Diseases2019-08-096 citations
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
New England Journal of Medicine2019-03-13346 citations
Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy Volunteers
Antimicrobial Agents and Chemotherapy2015-04-0121 citations